Accueil   Agenda - News   Toutes les news NETRIS PHARMA: CLINICAL TRIAL COLLABORATION AGREEMENT WITH MSD

NETRIS PHARMA: CLINICAL TRIAL COLLABORATION AGREEMENT WITH MSD

 

 

 

TO EVALUATE NP137 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN ADVANCED UTERINE AND CERVICAL TUMORS

 

Unique NP137 mechanism targeting netrin-1 could alleviate anti-PD-1 resistance

 

Lyon, France – May 5, 2020 - NETRIS Pharma SAS, a private clinical-stage biopharmaceutical company developing therapeutics based on dependence receptor biology, today announced that it has entered into a clinical collaboration agreement with MSD to investigate the safety, clinical and biological activity of NP137 with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with locally advanced/metastatic uterine tumors. NP137 targets netrin-1, which is overexpressed in over two-thirds of uterine tumors.

 

 

The companies have entered this collaboration based on promising clinical data obtained from a phase 1 trial investigating NP137 monotherapy in patients with advanced solid tumors and the growing evidence that resistance to an anti-PD-1 therapy, such as KEYTRUDA, can be alleviated when combined with blocking netrin-1.

 

Under the terms of the agreement, NETRIS will sponsor a large phase 1b/2 study, which will be conducted in collaboration with the Centre Léon Bérard and with support of the specialist French oncology group of clinicians, GINECO (Groupe d’Investigateurs National des Etudes des Cancers Ovariens). The study will investigate the safety and efficacy of NP137 combined with KEYTRUDA in patients with advanced/metastatic endometrial carcinoma or cervix carcinoma.

 

Lire le communiqué de presse